We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+29.57%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.61B
AUM Growth
+$310M
(+24%)
Cap. Flow
+$124M
Cap. Flow
% of AUM
7.72%
Top 10 Holdings %
Top 10 Hldgs %
66.37%
Holding
50
New
7
Increased
9
Reduced
5
Closed
6
Avg Time Held
0.6
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NewAmsterdam Pharma
NAMS
|
+$92.8M |
| 2 |
IMGO
Imago BioSciences, Inc. Common stock
IMGO
|
+$25.4M |
| 3 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$10.7M |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$9.54M |
| 5 |
KalVista Pharmaceuticals
KALV
|
+$8.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
+$26.7M |
| 2 |
FLACU
Frazier Lifesciences Acquisition Corporation Unit
FLACU
|
+$15.2M |
| 3 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$9.31M |
| 4 |
Vaxcyte
PCVX
|
+$5.89M |
| 5 |
MacroGenics
MGNX
|
+$2.43M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.97% |
| 2 | Miscellaneous | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $12.4M | 0.77% |
393,000
| – | – |
2022 Q1
3 quarters
|
|
27
DELISTED
Merus
MRUS
| $11.5M | 0.72% |
746,479
| – | – |
2022 Q1
3 quarters
|
|
|
VECT
28
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $11.5M | 0.71% |
+1,333,400
| New | +$10.7M |
2022 Q4
0 quarters
|
|
|
RNAM
29
DELISTED
Avidity Biosciences
RNAM
| $11.1M | 0.69% |
+500,000
| New | +$7.46M |
2022 Q4
0 quarters
|
|
30
Immunovant
IMVT
$5.83B
| $10.4M | 0.65% |
585,759
| – | – |
2022 Q1
3 quarters
|
|
31
Tyra Biosciences
TYRA
$1.32B
| $10.1M | 0.63% |
1,327,665
| – | – |
2022 Q1
3 quarters
|
|
32
DELISTED
bluebird bio
BLUE
| $9.97M | 0.62% |
72,038
| – | – |
2022 Q3
1 quarter
|
|
33
Arvinas
ARVN
$460M
| $9.76M | 0.61% |
285,331
| – | – |
2022 Q1
3 quarters
|
|
34
Prothena Corp
PRTA
$441M
| $7.71M | 0.48% |
+127,900
| New | +$7.49M |
2022 Q4
0 quarters
|
|
35
Autolus Therapeutics
AUTL
$458M
| $7.12M | 0.44% |
3,746,857
| – | – |
2022 Q1
3 quarters
|
|
36
Intellia Therapeutics
NTLA
$1.58B
| $7.11M | 0.44% |
203,684
| – | – |
2022 Q1
3 quarters
|
|
|
THRX
37
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $6.96M | 0.43% |
+1,398,194
| New | +$8.19M |
2022 Q4
0 quarters
|
|
38
Passage Bio
PASG
$11.6M
| $5.18M | 0.32% |
187,846
| – | – |
2022 Q1
3 quarters
|
|
39
Zymeworks
ZYME
$1.86B
| $4.79M | 0.3% |
+610,000
| New | +$4.29M |
2022 Q4
0 quarters
|
|
40
Aclaris Therapeutics
ACRS
$509M
| $4.57M | 0.28% |
290,189
-118,140
| -29% | -$1.9M |
2022 Q1
3 quarters
|
|
41
DELISTED
ESSA Pharma
EPIX
| $1.52M | 0.09% |
605,141
-87,769
| -13% | -$252K |
2022 Q1
3 quarters
|
|
|
APTX
42
DELISTED
Aptinyx Inc. Common Stock
APTX
| $537K | 0.03% |
1,883,244
| – | – |
2022 Q1
3 quarters
|
|
|
43
NewAmsterdam Pharma Warrant
NAMSW
| $434K | 0.03% |
+500,333
| New | +$412K |
2022 Q4
0 quarters
|
|
|
NBRV
44
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $32.2K | ﹤0.01% |
17,025
| – | – |
2022 Q1
3 quarters
|
|
|
45
MacroGenics
MGNX
$215M
| – | – |
-701,631
| Closed | -$2.43M | – |
|
|
GRCL
46
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| – | – |
-2,890,102
| Closed | -$9.31M | – |
|
|
PRDS
47
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| – | – |
-845,636
| Closed | -$1.56M | – |
|
48
DELISTED
Molecular Templates, Inc.
MTEM
| – | – |
-91,603
| Closed | -$1.03M | – |
|
|
TCDA
49
DELISTED
Tricida, Inc. Common Stock
TCDA
| – | – |
-2,549,671
| Closed | -$26.7M | – |
|
|
FLACU
50
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
| – | – |
-1,501,000
| Closed | -$15.2M | – |
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q4 2022 Portfolio in Review
As of Q4 2022, Frazier Life Sciences Management held 50 positions worth $1.61B, up 24% from $1.3B the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Frazier Life Sciences Management deployed $124M of net new capital in Q4 2022, opening 7 new positions and adding to 9 existing holdings. Its largest new stake was NewAmsterdam Pharma: 9,341,551 shares worth $102M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Vaxcyte, an estimated $5.89M trimmed.
- Frazier Life Sciences Management's largest Q4 2022 buy was NewAmsterdam Pharma: 9,341,551 shares worth $102M.
- Frazier Life Sciences Management added most to Imago BioSciences, Inc. Common stock in Q4 2022, an estimated $25.4M increase.
- Frazier Life Sciences Management's biggest Q4 2022 reduction was Vaxcyte, cutting an estimated $5.89M.
- Frazier Life Sciences Management fully exited Tricida, Inc. Common Stock in Q4 2022, selling an estimated $26.7M.
- Frazier Life Sciences Management's ten largest holdings make up 66% of its $1.61B portfolio in Q4 2022.
- Frazier Life Sciences Management opened 7 new positions and closed 6 in Q4 2022.
- Frazier Life Sciences Management's portfolio value rose 24% quarter-over-quarter to $1.61B.
Based on Frazier Life Sciences Management's 13F filing for Q4 2022, filed 3 Feb 2023.